"Big Pharma involvement in IL-12 is fading fast. Days after Bristol Myers Squibb punted its IL-12 fusion protein, AstraZeneca has jettisoned a gene therapy to dial down its interest in the cytokine for the second time in as many quarters."
CleverLibre Social is an inclusive social instance for open discussion, learning, and community.
All cultures welcome.
Hate speech and harassment strictly forbidden.